Added to YB: 2026-02-24
Pitch date: 2026-02-20
TEVA [neutral]
Teva Pharmaceutical Industries Limited
-1.31%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$39.9B
Pitch Price
$106.50
Price Target
60.00 (-43%)
Dividend
N/A
EV/EBITDA
10.49
P/E
28.28
EV/Sales
3.10
Sector
Pharmaceuticals
Category
growth
($TEVA) TL1A paradigm - engineering a Best-in-Class biological
TEVA (update): Duvakitug Phase 2b maintenance data shows best-in-class TL1A results: 58% clinical remission in UC, 55% endoscopic response in CD vs peers' 32-48%. Q4W dosing, low 3-5% immunogenicity. Sanofi 50/50 deal de-risks Phase 3. Peak sales est $2.7-5B. Debt down, pivot to growth validated. Price target $58-60 (24-36mo), ~11-12x 2028 P/E.
Read full article (4 min)